A biotech startup receives $2.4 million in seed funding. They spend 35% on R&D, 25% on salaries, and 10% on equipment. The remainder is reserved for clinical trials. If trials cost $45,000 per trial, how many complete trials can they fund?

Sun, 03 May 2026 08:10:43 +0000

**A biotech startup receives $2.4 million in seed funding. They spend 35% on R&D, 25% on salaries, and 10% on equipment. The remainder is reserved for clinical trials. If trials cost $45,000 each, how many complete studies can they support?** In an era where life sciences innovation is accelerating, this breakthrough biotech startup’s $2.4 million seed round is driving quiet excitement across research and investment circles. The allocation—35% toward groundbreaking R&D, 25% for talent and team growth, and 10% for lab needs—reflects a disciplined path toward turning scientific promise into real-world impact. With an eye on advancing therapies, the funding also enables critical clinical trials, where cost efficiency shapes progress. Understanding how those funds translate into action reveals not just numbers, but the momentum behind medical advancement. --- **Why A biotech startup receives $2.4 million in seed funding. They spend 35% on R&D, 25% on salaries, and 10% on equipment. The remainder is reserved for clinical trials. If trials cost $45,000 per trial, how many complete trials can they fund?**